Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

423
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
423
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

160
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
160
Clinical Trials01:16

Clinical Trials

7.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.2K
Actuarial Approach01:20

Actuarial Approach

115
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
115
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

175
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
175

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment.

Therapeutic advances in medical oncology·2026
Same author

Pan-cancer spatial atlas of tertiary lymphoid structures.

Science (New York, N.Y.)·2026
Same author

CXCL13-CXCR5 Signaling in CD8<sup>+</sup> T Cell Recruitment and Lymphoid Immune Organization in Clear Cell Renal Cell Carcinoma.

bioRxiv : the preprint server for biology·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Kidney Cancer Trends, Risk Factors, and Interventions in American Indian and Alaska Native Populations: The Kidney Cancer Association Scientific Statement.

Cancers·2026
Same author

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Cancer discovery·2026

Related Experiment Video

Updated: Aug 25, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K

Risk Model Development and Validation in Clinical Oncology: Lessons Learned.

Gary H Lyman1, Pavlos Msaouel2, Nicole M Kuderer3

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Cancer Investigation
|October 18, 2022
PubMed
Summary

Developing reliable clinical oncology risk models requires careful attention to data quality, missing data, sample size, and variable selection. Rigorous internal validation is crucial for ensuring model stability and quality in patient-centered decision-making.

Keywords:
Risk modelsprognostic modelsprognostic nomograms

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Related Experiment Videos

Last Updated: Aug 25, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Decision Support

Background:

  • Patient-centered care relies on accurate risk predictions.
  • Clinical oncology utilizes risk models for treatment and prognosis.
  • Effective risk modeling is essential for informed clinical decisions.

Purpose of the Study:

  • To summarize key considerations for developing robust risk models in clinical oncology.
  • To highlight often-overlooked challenges in clinical risk modeling.
  • To emphasize the importance of model validation.

Main Methods:

  • Review and synthesis of critical factors in clinical risk model development.
  • Identification of common pitfalls in data handling and model construction.
  • Emphasis on rigorous validation techniques.

Main Results:

  • Data quality and missing data significantly impact model reliability.
  • Effective sample size estimation is critical for statistical power.
  • Variable selection influences model generalizability and performance.
  • Internal validation is paramount for assessing model stability and accuracy.

Conclusions:

  • Addressing data quality, missing data, sample size, and variable selection are crucial for reliable oncology risk models.
  • Rigorous internal validation is essential to ensure the stability and quality of risk models.
  • Improved risk models enhance patient-centered inferences and decision-making in clinical oncology.